337 related articles for article (PubMed ID: 9635566)
1. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
[TBL] [Abstract][Full Text] [Related]
2. Biologic activities of natural and synthetic type I interferons.
Pfeffer LM
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-63-S9-69. PubMed ID: 9208874
[TBL] [Abstract][Full Text] [Related]
3. New developments in interferon therapy.
Tossing G
Eur J Med Res; 2001 Feb; 6(2):47-65. PubMed ID: 11313191
[TBL] [Abstract][Full Text] [Related]
4. Biological basis for a proper clinical application of alpha interferons.
Antonelli G
New Microbiol; 2008 Jul; 31(3):305-18. PubMed ID: 18843884
[TBL] [Abstract][Full Text] [Related]
5. Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon.
Walter MR; Bordens R; Nagabhushan TL; Williams BR; Herberman RB; Dinarello CA; Borden EC; Trotta PP; Pestka S; Pfeffer LM
Cancer Biother Radiopharm; 1998 Jun; 13(3):143-54. PubMed ID: 10850350
[TBL] [Abstract][Full Text] [Related]
6. Second-generation interferons for cancer: clinical targets.
Borden EC; Lindner D; Dreicer R; Hussein M; Peereboom D
Semin Cancer Biol; 2000 Apr; 10(2):125-44. PubMed ID: 10936063
[TBL] [Abstract][Full Text] [Related]
7. Interferons, interferon-like cytokines, and their receptors.
Pestka S; Krause CD; Walter MR
Immunol Rev; 2004 Dec; 202():8-32. PubMed ID: 15546383
[TBL] [Abstract][Full Text] [Related]
8. Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity.
Slutzki M; Jaitin DA; Yehezkel TB; Schreiber G
J Mol Biol; 2006 Jul; 360(5):1019-30. PubMed ID: 16815442
[TBL] [Abstract][Full Text] [Related]
9. [Alpha interferons--new therapeutic modalities].
Bajcetić M; Zigon N; Samardzić R; Beleslin DB
Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
[TBL] [Abstract][Full Text] [Related]
10. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
Khine AA; Lingwood CA
J Cell Physiol; 2000 Jan; 182(1):97-108. PubMed ID: 10567921
[TBL] [Abstract][Full Text] [Related]
11. Divergence of binding, signaling, and biological responses to recombinant human hybrid IFN.
Hu R; Bekisz J; Hayes M; Audet S; Beeler J; Petricoin E; Zoon K
J Immunol; 1999 Jul; 163(2):854-60. PubMed ID: 10395679
[TBL] [Abstract][Full Text] [Related]
12. [Interferon--a new therapeutic principle].
Micksche M
Wien Med Wochenschr; 1993; 143(16-17):408-12. PubMed ID: 8273362
[TBL] [Abstract][Full Text] [Related]
13. The human interferon alpha species and receptors.
Pestka S
Biopolymers; 2000; 55(4):254-87. PubMed ID: 11169919
[TBL] [Abstract][Full Text] [Related]
14. Interference by interferons: Janus faces in vascular proliferative diseases.
Wessely R
Cardiovasc Res; 2005 Jun; 66(3):433-43. PubMed ID: 15914108
[TBL] [Abstract][Full Text] [Related]
15. Type I interferons: ancient peptides with still under-discovered anti-cancer properties.
Caraglia M; Dicitore A; Marra M; Castiglioni S; Persani L; Sperlongano P; Tagliaferri P; Abbruzzese A; Vitale G
Protein Pept Lett; 2013 Apr; 20(4):412-23. PubMed ID: 23016588
[TBL] [Abstract][Full Text] [Related]
16. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions.
Pfeffer LM; Wang C; Constantinescu SN; Croze E; Blatt LM; Albino AP; Nanus DM
J Urol; 1996 Nov; 156(5):1867-71. PubMed ID: 8863634
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha as an immunotherapeutic protein.
Brassard DL; Grace MJ; Bordens RW
J Leukoc Biol; 2002 Apr; 71(4):565-81. PubMed ID: 11927642
[TBL] [Abstract][Full Text] [Related]
18. Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases.
Dec M; Puchalski A
Pol J Vet Sci; 2008; 11(2):175-86. PubMed ID: 18683548
[TBL] [Abstract][Full Text] [Related]
19. The interferons.
Itri LM
Cancer; 1992 Aug; 70(4 Suppl):940-5. PubMed ID: 1379116
[TBL] [Abstract][Full Text] [Related]
20. Interferon at 50: new molecules, new potential, new (and old) questions.
Langer JA
Sci STKE; 2007 Sep; 2007(405):pe53. PubMed ID: 17895481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
